19th April 2018
- 0 comments
Zelluna Immunotherapy, the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, has announced the appointment of Arjan Roozen as chief technology officer (CTO).
...In order to read the full story we need you to be registered with us, please click the links below to login or register.